Core Viewpoint - Evolv Technologies Holdings, Inc. (EVLV) shares have seen a 0.7% increase over the past four weeks, closing at $6.77, with a potential upside of 45.9% based on Wall Street analysts' mean price target of $9.88 [1][2] Price Targets and Analyst Estimates - The mean estimate consists of four short-term price targets with a standard deviation of $0.25, indicating a consensus among analysts. The lowest estimate of $9.50 suggests a 40.3% increase, while the highest target of $10.00 indicates a 47.7% increase [2] - A low standard deviation signifies a high degree of agreement among analysts regarding the stock's price movement, which can serve as a starting point for further research [9] Earnings Estimates and Market Sentiment - Analysts are optimistic about EVLV's earnings prospects, as indicated by a positive trend in earnings estimate revisions. The Zacks Consensus Estimate for the current year has increased by 15% over the past month, with no negative revisions [11][12] - EVLV holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates, suggesting a strong potential upside in the near term [13] Caution on Price Targets - While the consensus price target is a commonly referenced metric, it should not be the sole basis for investment decisions due to the questionable reliability of analysts in setting these targets [3][10] - Analysts may set overly optimistic price targets influenced by business relationships, which can lead to inflated expectations [8]

Core Viewpoint - Byrna Technologies Inc. (BYRN) has been upgraded to a Zacks Rank 2 (Buy), indicating a positive outlook on its earnings estimates, which is a significant factor influencing stock prices [1][3]. Earnings Estimates and Stock Price Movement - The Zacks rating system is based on changes in earnings estimates, which are strongly correlated with near-term stock price movements [4][6]. - Institutional investors often rely on earnings estimates to determine the fair value of stocks, leading to buying or selling actions that affect stock prices [4]. Byrna Technologies' Earnings Outlook - Byrna Technologies is projected to earn $0.40 per share for the fiscal year ending November 2025, with no year-over-year change expected [8]. - Over the past three months, the Zacks Consensus Estimate for Byrna Technologies has increased by 6.1%, reflecting a positive trend in earnings estimates [8]. Zacks Rank System - The Zacks Rank system classifies stocks into five groups based on earnings estimates, with a strong historical performance, particularly for Zacks Rank 1 stocks, which have generated an average annual return of +25% since 1988 [7]. - The upgrade of Byrna Technologies to a Zacks Rank 2 places it in the top 20% of Zacks-covered stocks, suggesting potential for market-beating returns in the near term [10].

Core Viewpoint - Rentokil Initial PLC (RTO) has received an upgrade to a Zacks Rank 2 (Buy), indicating a positive outlook on its earnings estimates, which is a significant factor influencing stock prices [1][3]. Earnings Estimates and Stock Price Movement - The Zacks rating system emphasizes the importance of earnings estimate revisions, which have shown a strong correlation with near-term stock price movements [4][6]. - An increase in earnings estimates typically leads to higher fair value calculations by institutional investors, resulting in buying or selling actions that affect stock prices [4]. Company Performance Indicators - Rentokil Initial is projected to earn $1.28 per share for the fiscal year ending December 2025, with no year-over-year change expected [8]. - Over the past three months, the Zacks Consensus Estimate for Rentokil Initial has increased by 0.3%, reflecting a positive trend in earnings estimates [8]. Zacks Rank System - The Zacks Rank system classifies stocks based on earnings estimates into five groups, with only the top 20% receiving a "Strong Buy" or "Buy" rating, indicating superior earnings estimate revisions [9][10]. - The upgrade of Rentokil Initial to a Zacks Rank 2 places it in the top 20% of Zacks-covered stocks, suggesting potential for market-beating returns in the near term [10].

Core Viewpoint - Howmet (HWM) has received an upgrade to a Zacks Rank 2 (Buy), indicating a positive trend in earnings estimates which is a significant factor influencing stock prices [1][2]. Earnings Estimates and Stock Price Movement - The Zacks rating system is based on changes in earnings estimates, which are strongly correlated with near-term stock price movements [3][5]. - Institutional investors utilize earnings estimates to determine the fair value of stocks, leading to buying or selling actions that affect stock prices [3]. Company Performance and Outlook - The upgrade for Howmet reflects an improvement in the company's underlying business, suggesting that investor sentiment regarding this trend could drive the stock price higher [4]. - For the fiscal year ending December 2025, Howmet is expected to earn $3.69 per share, with a 2.9% increase in the Zacks Consensus Estimate over the past three months [7]. Zacks Rank System - The Zacks Rank system classifies stocks into five groups based on earnings estimates, with a proven track record of Zacks Rank 1 stocks generating an average annual return of +25% since 1988 [6]. - The upgrade of Howmet to a Zacks Rank 2 places it in the top 20% of Zacks-covered stocks, indicating strong potential for market-beating returns in the near term [9].

Core Viewpoint - Staar Surgical (STAA) has been upgraded to a Zacks Rank 2 (Buy), indicating a positive trend in earnings estimates which is a significant factor influencing stock prices [1][3]. Earnings Estimates and Stock Price Impact - The Zacks rating system is based on changes in earnings estimates, which are strongly correlated with near-term stock price movements [4][6]. - Institutional investors utilize earnings estimates to determine the fair value of stocks, leading to buying or selling actions that affect stock prices [4]. Business Improvement Indicators - The upgrade in earnings estimates for Staar Surgical suggests an improvement in the company's underlying business, which could lead to increased stock prices as investors respond positively [5][10]. - Over the past three months, the Zacks Consensus Estimate for Staar Surgical has increased by 16.9%, reflecting a positive outlook [8]. Zacks Rank System Overview - The Zacks Rank system classifies stocks into five groups based on earnings estimates, with only the top 20% receiving a "Strong Buy" or "Buy" rating, indicating superior earnings estimate revisions [9][10]. - Stocks rated Zacks Rank 1 have historically generated an average annual return of +25% since 1988, showcasing the effectiveness of the rating system [7].

McGraw Hill, Inc. (MH) closed the last trading session at $16.68, gaining 51% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $20.92 indicates a 25.4% upside potential.The average comprises 12 short-term price targets ranging from a low of $16.00 to a high of $26.00, with a standard deviation of $2.71. While the lowest estimate indicates a decline of 4.1% from the current price lev ...

Core Viewpoint - Tetra Tech (TTEK) shows potential for further upside, with a mean price target of $42.4 indicating a 26.3% increase from its current price of $33.58 [1] Price Targets - The average price target consists of five estimates ranging from a low of $38.00 to a high of $48.00, with a standard deviation of $3.65, suggesting a consensus among analysts [2] - The lowest estimate indicates a 13.2% increase, while the highest suggests a 42.9% upside [2] - A low standard deviation indicates greater agreement among analysts regarding price movement [9] Analyst Sentiment - Analysts are optimistic about TTEK's earnings prospects, as evidenced by upward revisions in EPS estimates, which correlate with potential stock price increases [11] - Over the last 30 days, the Zacks Consensus Estimate for the current year has risen by 1.4%, with one estimate increasing and no negative revisions [12] - TTEK holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13] Caution on Price Targets - While price targets are commonly referenced, they can mislead investors, as empirical research shows they often do not accurately predict stock price movements [7][10] - Analysts may set optimistic price targets due to business incentives, which can inflate expectations [8]

Core Viewpoint - EverQuote (EVER) shows potential for upside with a mean price target of $33.67, indicating a 26% increase from the current price of $26.72 [1] Price Targets - The average price target consists of six estimates ranging from $30.00 to $40.00, with a standard deviation of $3.83, suggesting a consensus among analysts [2] - The lowest estimate indicates a 12.3% increase, while the highest suggests a 49.7% upside [2] - A low standard deviation indicates greater agreement among analysts regarding price movement [2][9] Analyst Sentiment - Analysts have shown increasing optimism about EverQuote's earnings, with a positive trend in earnings estimate revisions [4][11] - Over the last 30 days, two estimates have been revised higher, leading to a 3.6% increase in the Zacks Consensus Estimate [12] Zacks Rank - EverQuote holds a Zacks Rank 1 (Strong Buy), placing it in the top 5% of over 4,000 ranked stocks based on earnings estimates [13] Conclusion on Price Movement - While consensus price targets may not reliably indicate the extent of potential gains, they do suggest a positive direction for price movement [14]

Core Viewpoint - Royal Gold (RGLD) has shown a 7.4% increase in stock price over the past four weeks, with a mean price target of $249.89 indicating a potential upside of 26% from the current price of $198.33 [1] Price Targets and Analyst Estimates - The mean estimate consists of nine short-term price targets with a standard deviation of $21.29, where the lowest estimate is $205.00 (3.4% increase) and the highest is $280.00 (41.2% increase) [2] - A low standard deviation suggests a strong agreement among analysts regarding the stock's price movement, which can serve as a starting point for further research [9] Earnings Estimates and Analyst Optimism - Analysts have shown growing optimism regarding RGLD's earnings prospects, as indicated by a positive trend in earnings estimate revisions, which correlates with near-term stock price movements [11] - Over the last 30 days, the Zacks Consensus Estimate for the current year has increased by 0.1%, with one estimate moving higher and no negative revisions [12] Zacks Rank and Investment Potential - RGLD currently holds a Zacks Rank 1 (Strong Buy), placing it in the top 5% of over 4,000 ranked stocks based on earnings estimates, indicating strong potential for upside in the near term [13] Caution on Price Targets - While the consensus price target is a useful metric, relying solely on it for investment decisions may not be wise due to the questionable ability of analysts in setting accurate price targets [3][10]

CorMedix (CRMD) closed the last trading session at $11.26, gaining 1.6% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $19 indicates a 68.7% upside potential.The mean estimate comprises seven short-term price targets with a standard deviation of $3.11. While the lowest estimate of $14.00 indicates a 24.3% increase from the current price level, the most optimistic analyst expects t ...